Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.76 |
| ▸ | HTR1A | P08908 | 9/20 | 0.76 |
| ▸ | HTR1D | P28221 | 9/20 | 0.76 |
| ▸ | HTR1B | P28222 | 9/20 | 0.76 |
| ▸ | HTR2C | P28335 | 7/20 | 0.76 |
| ▸ | HTR7 | P34969 | 6/20 | 0.76 |
| ▸ | DRD2 | P14416 | 6/20 | 0.76 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.76 |
| ▸ | DRD3 | P35462 | 6/20 | 0.76 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.76 |
| ▸ | HTR2A | P28223 | 5/20 | 0.76 |
| ▸ | DRD1 | P21728 | 1/20 | 0.76 |
| ▸ | DRD4 | P21917 | 1/20 | 0.76 |
| ▸ | HTR2B | P41595 | 6/20 | 0.75 |
| ▸ | HTR3A | P46098 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6974380 | 0.90 | HTR6 (0.76) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL29386932 | 0.86 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL194700 | 0.86 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| Hydrochloric Acid SCHEMBL6977773 | 0.86 | HTR6 (1.00) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL7199110 | 0.85 | HTR6 (0.82) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6973742 | 0.80 | HTR6 (0.80) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6983122 | 0.79 | HTR6 (0.65) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6975332 | 0.78 | HTR6 (0.80) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL6980929 | 0.78 | HTR6 (0.85) | HTR6HTR1AHTR1DHTR1BHTR2C | |
| SCHEMBL13683254 | 0.77 | HTR6 (0.83) | HTR6HTR1AHTR1DHTR1BHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-1301475-B1 | ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY | BIOVITRUM AB (SE) | 2006-11-22 | — | — | EP | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| US-6399617-B1 | ADMINISTERING ARYL SULFONAMIDE COMPOUND FOR PROPHYLAXIS OR THERAPY OF OBESITY | BIOVITRUM AB (SE) | 2002-06-04 | — | — | US | claimed |
| US-20020058655-A1 | NEW USE | BIOVITRUM AB (SE) | 2002-05-16 | — | — | US | claimed |
| EP-2301625-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2017-07-19 | — | — | EP | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| EP-2521714-B1 | Aromatic sulfone compounds useful in the treatment of central nervous disorders | SUVEN LIFE SCIENCES LTD (IN) | 2015-08-12 | — | — | EP | disclosed |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | RESILIO COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
| US-9018231-B2 | Sulfone compounds as 5-HT6 receptor ligands | SUVEN LIFE SCIENCES LIMITED (IN) | 2015-04-28 | — | — | US | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| US-20090054489-A1 | Multimediator Dopamine Transport Inhibitors, and Uses Related Thereto | PREXA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007138611-A1 | 3-(HETEROCYCLYL)-N-(ARYLSULFONYL)INDOLE DERIVATIVES AS FUNCTIONAL 5-HT6 LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-12-06 | — | — | WO | disclosed |
| EP-1301475-B1 | ARYL SULFONAMIDES AS SEROTONIN ANTAGONIST FOR THE TREATMENT OF OBESITY | BIOVITRUM AB (SE) | 2006-11-22 | — | — | EP | disclosed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | disclosed |
| US-6399617-B1 | ADMINISTERING ARYL SULFONAMIDE COMPOUND FOR PROPHYLAXIS OR THERAPY OF OBESITY | BIOVITRUM AB (SE) | 2002-06-04 | — | — | US | disclosed |
| US-20020058655-A1 | NEW USE | BIOVITRUM AB (SE) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885HTR1A 5/4885HTR1D 20/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | HTR6 3655/4885HTR1A 4002/4885HTR1D 4420/4885 |
| US-20150126464-A1 | THERAPEUTIC DRUG AND THERAPEUTIC METHOD FOR NEUROLOGICAL DISEASES INCLUDING ALZHEIMER'S DISEASE ASSOCIATED WITH 1,25D3-MARRS | BDNF, BACE1, GAP43 | HTR6 1206/4885HTR1A 326/4885HTR1D 361/4885 |
| US-20020058655-A1 | NEW USE | SULT2A1, SULT1A1, GPR119 | HTR6 1581/4885HTR1A 881/4885HTR1D 1361/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | HTR6 400/4885HTR1A 343/4885HTR1D 537/4885 |
| US-20090054489-A1 | Multimediator Dopamine Transport Inhibitors, and Uses Related Thereto | SLC6A2, SLC6A3, SLC6A4 | HTR6 14/4885HTR1A 8/4885HTR1D 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.